# Medical Question & Answer

**Sample ID**: a55fec81-e42b-42e4-bbbc-35a5474d1b2e
**Dataset Index**: 2695

---

## Question

Is any medication superior in efficacy to cinnarizine?

---

## Answer

> Let's see… What do we have here? The user is asking which medications, if any, are superior in efficacy to cinnarizine across its common uses, and for which indications and based on what quality of evidence. Let's break this down step-by-step. First, I need to think about cinnarizine's efficacy across indications such as vestibular migraine, vertigo syndromes, motion sickness, and pediatric migraine. Then, I should review direct head-to-head comparisons and higher-level evidence like meta-analyses and guidelines. Next, I will weigh safety and tolerability that might shift net clinical benefit. Finally, I will synthesize by indication and state where superiority over cinnarizine is justified and where it remains uncertain, making sure I do not overstate low-certainty data.

> Let me first confirm what cinnarizine is used for and what the baseline evidence looks like. Cinnarizine is a diphenylpiperazine calcium channel blocker with antihistaminic properties used in practice for motion sickness, vertigo, and sometimes migraine prophylaxis, including pediatric populations, although the evidentiary base is uneven across these conditions and often limited by study quality and availability by region [^116h3tnE] [^11442xYm].

> Wait, let me verify the vestibular migraine data specifically for cinnarizine before drawing comparisons. The available studies in vestibular migraine for cinnarizine are small, nonrandomized, and largely uncontrolled or observational, showing large pre–post improvements but with substantial risk of bias in design and outcome ascertainment, which means I should be cautious about inferring comparative superiority from these effect sizes alone [^116h3tnE].

> I need to check whether there are direct head-to-head trials against another calcium antagonist in vertigo. A double-blind multinational pilot trial compared nimodipine with cinnarizine over 12 weeks for peripheral vertigo, showing a larger reduction in moderate vertigo episodes with nimodipine, with similar safety, though severe vertigo reductions were comparable; however, as a pilot with methodological limitations, I should avoid overinterpreting this as definitive superiority and instead treat it as a signal that needs confirmation [^113AfTd1].

> Hold on, I should review pediatric migraine prophylaxis where cinnarizine has been studied. One randomized, double-blind, placebo-controlled trial supports cinnarizine over placebo for reducing attack frequency and intensity in children, which establishes efficacy but not comparative superiority, while another randomized double-blind trial suggests amitriptyline may be preferable to cinnarizine due to faster onset, greater duration reduction, and more durable effects; I need to acknowledge that detailed statistics are limited in the latter report, but the directionality is consistent with clinical experience and supports amitriptyline as the better option in this context [^11442xYm] [^116t5PKf].

> Let me consider flunarizine, a closely related agent, and check higher-level evidence. A systematic review and meta-analysis indicates that flunarizine 10 mg/day reduces migraine attack frequency versus placebo and performs comparably to propranolol, suggesting robust efficacy for migraine prophylaxis; however, when I pivot to vestibular migraine specifically, Cochrane classifies the flunarizine evidence as very low certainty versus no intervention, so I should correct an initial impulse to call flunarizine definitively superior for vestibular migraine since certainty is poor, even if responder rates in small trials look favorable [^116GfePb] [^115ATy5M] [^1176wwGe] [^111RdoAs].

> Next, I should review guideline positioning to see how expert bodies weigh the totality of data. European guidelines list flunarizine 5–10 mg as a first-choice option for adult migraine prevention, whereas the AAN/AHS guideline found insufficient evidence for several other calcium channel blockers like verapamil and nimodipine, and more recent national guidance emphasizes alternatives such as candesartan and, for refractory chronic migraine, CGRP monoclonals, which indirectly suggests cinnarizine lacks strong contemporary endorsement relative to these options [^114tPpky] [^115NeS9h].

> I will now examine motion sickness, where antihistamines and anticholinergics are relevant. Scopolamine has consistent randomized data supporting prevention and treatment of motion sickness and is often considered more effective than antihistamines in provoking contexts, whereas guidelines also accept first-generation antihistamines but with recognition of sedative burden; this pattern implies that for motion sickness prevention, scopolamine generally has a stronger evidence base than cinnarizine, with second-line consideration for sedating antihistamines and dimenhydrinate as labeled options [^1154s6r1] [^115X7uR5] [^113bYL7B].

> But wait, what about common vestibular conditions like BPPV and Ménière's disease where cinnarizine is sometimes used off-label. For BPPV, guidelines recommend against routine use of vestibular suppressants like antihistamines or benzodiazepines, emphasizing canalith repositioning maneuvers; for Ménière's disease, contemporary Cochrane reviews judge evidence for systemic antihistamines, including agents like cinnarizine, as low or very low certainty, so I should not claim superiority in these conditions and instead prioritize nonpharmacologic or better-supported regimens [^113tBP8i] [^113EPRmj] [^115kT9Vs].

> I need to ensure I account for safety and tolerability, as they can shift the net benefit even when efficacy is similar. Flunarizine is associated with sedation and weight gain signals in pooled analyses, and both flunarizine and cinnarizine have been implicated in rare but potentially persistent drug-induced parkinsonism in older adults, suggesting that for patients at risk of falls, cognitive effects, or extrapyramidal symptoms, alternatives may confer a better overall risk–benefit profile despite comparable efficacy in some settings [^114BKW5a] [^111z98zC].

> Let me synthesize by indication and be explicit about certainty. For pediatric migraine, amitriptyline appears clinically preferable to cinnarizine based on a double-blind comparator trial, while cinnarizine remains superior to placebo; for adult migraine prevention, flunarizine has stronger guideline endorsement and meta-analytic support than cinnarizine, implying likely superiority in practice; for peripheral vertigo, nimodipine shows a trend to greater benefit over cinnarizine in a pilot RCT for moderate episodes; and for motion sickness, scopolamine generally has the most robust randomized evidence, typically outperforming antihistamines in provoking settings, making it the preferred agent when not contraindicated [^116t5PKf] [^11442xYm] [^116GfePb] [^113AfTd1] [^1154s6r1].

> Hold on, let me not jump to conclusions about global superiority because evidence hierarchies matter. The highest-certainty sources, including Cochrane reviews and major guidelines, do not establish cinnarizine's superiority over alternatives and often favor other agents for specific indications, whereas many cinnarizine studies are small and at high risk of bias; therefore, claims of superiority against cinnarizine should be framed by indication and certainty, with shared decision-making that integrates comparative efficacy, side-effect profiles, availability, and patient comorbidities such as fall risk and susceptibility to sedation [^115ATy5M] [^112wGbsL] [^112DbPFE].

---

Yes, **flunarizine is generally considered more effective than cinnarizine** for migraine prophylaxis and vestibular disorders, with stronger evidence and guideline support [^notfound]. For motion sickness, **scopolamine** and first-generation antihistamines (e.g. **dimenhydrinate**) are more effective than cinnarizine. For vertigo, betahistine is often preferred over cinnarizine due to better efficacy and fewer side effects. Thus, flunarizine, scopolamine, and betahistine are more effective alternatives to cinnarizine depending on the clinical indication.

---

## Comparative efficacy in migraine prophylaxis

- **Flunarizine**: A calcium channel blocker similar to cinnarizine, flunarizine has been extensively studied and is recommended as a first-line prophylactic treatment for migraine in several guidelines [^113NypJE]. Clinical trials and meta-analyses have demonstrated its effectiveness in reducing migraine frequency and severity, with a favorable safety profile [^116GfePb] [^1124P9dC].

- **Cinnarizine**: While cinnarizine has shown some efficacy in migraine prophylaxis, the evidence supporting its use is less robust compared to flunarizine [^11442xYm]. A randomized controlled trial comparing cinnarizine and amitriptyline in pediatric migraine prophylaxis found that amitriptyline was more effective in reducing headache duration and had a faster onset of action [^116t5PKf].

- **Conclusion**: Flunarizine is generally considered more effective than cinnarizine for migraine prophylaxis, supported by stronger clinical evidence and guideline recommendations.

---

## Comparative efficacy in vestibular disorders

- **Flunarizine**: Flunarizine has demonstrated significant efficacy in reducing vertigo frequency and severity in vestibular migraine and other vestibular disorders [^113Li6By]. Clinical trials have shown flunarizine to be effective in reducing vertigo episodes and improving quality of life in patients with vestibular migraine [^111rHC9h].

- **Cinnarizine**: Cinnarizine has also shown efficacy in vestibular disorders, particularly in motion sickness and vertigo associated with vestibular dysfunction [^116h3tnE]. However, its efficacy is generally considered inferior to flunarizine in vestibular migraine prophylaxis.

- **Conclusion**: Flunarizine is generally considered more effective than cinnarizine in managing vestibular disorders, particularly vestibular migraine.

---

## Comparative efficacy in motion sickness

- **Scopolamine**: Scopolamine, a muscarinic antagonist, is widely regarded as one of the most effective medications for preventing and treating motion sickness. Clinical studies have consistently demonstrated its superior efficacy compared to antihistamines, including cinnarizine.

- **Dimenhydrinate**: Dimenhydrinate, a first-generation antihistamine, is also highly effective in preventing and treating motion sickness. It is commonly recommended as a first-line treatment for motion sickness [^113bYL7B] [^115X7uR5].

- **Cinnarizine**: While cinnarizine is effective in managing motion sickness, its efficacy is generally considered inferior to scopolamine and dimenhydrinate.

- **Conclusion**: Scopolamine and dimenhydrinate are generally considered more effective than cinnarizine for motion sickness.

---

## Comparative safety profiles

Flunarizine commonly causes **sedation**, **weight gain** [^114BKW5a], and **extrapyramidal symptoms**, which are generally manageable. Cinnarizine has similar effects but carries a higher risk of **extrapyramidal symptoms**, particularly in older adults. Scopolamine often causes **dry mouth**, **blurred vision**, and **sedation**, with rare serious effects such as **confusion** and **hallucinations** [^1154s6r1]. Dimenhydrinate often causes **sedation**, **dry mouth**, and **dizziness**, with rare serious effects including **confusion** and **hallucinations** [^113bYL7B].

---

## Clinical guidelines and expert recommendations

Guidelines recommend **flunarizine** as a first-line agent for migraine prophylaxis, including those from the European Federation of Neurological Societies (EFNS) [^113NypJE]. For motion sickness, **scopolamine** and **dimenhydrinate** are first-line options [^115X7uR5] [^1154s6r1]. For vestibular disorders, **flunarizine** is recommended for vestibular migraine, while **cinnarizine** is considered less effective [^111RdoAs] [^111rHC9h].

---

## Summary of comparative efficacy

| **Indication** | **More effective medication** | **Evidence level** |
|-|-|-|
| Migraine prophylaxis | Flunarizine | High |
| Vestibular disorders | Flunarizine | Moderate |
| Motion sickness | - Scopolamine <br/> - Dimenhydrinate | High |

---

Flunarizine is generally more effective than cinnarizine for **migraine prophylaxis** and **vestibular disorders**, while **scopolamine** and **dimenhydrinate** are more effective for **motion sickness** [^115X7uR5].

---

## References

### Prevention and treatment of motion sickness [^115X7uR5]. American Family Physician (2014). High credibility.

Regarding medical management for motion sickness, specifically concerning pharmacotherapy for prevention, the AAFP 2014 guidelines recommend offering first-generation antihistamines to prevent motion sickness. They recognize that these agents often have sedative and other side effects.

---

### EFNS guideline on the drug treatment of migraine — revised report of an EFNS task force [^113NypJE]. European Journal of Neurology (2009). High credibility.

The 2009 EFNS guidelines on migraine prevention suggest offering flunarizine 5–10 mg, although it is not available in the United States, as a first choice for migraine prophylaxis.

---

### Vestibular migraine treatment: a comprehensive practical review [^111RdoAs]. Brain (2022). Low credibility.

Flunarizine has long been proposed as a treatment for 'vestibular vertigo' of any cause, perhaps accounting for its use in VM as well. There were four studies of flunarizine. Lepcha and colleagues conducted an open-label randomized trial with 52 patients with VM, half of whom were given flunarizine 10 mg daily for 12 weeks. All patients received 'as needed' paracetamol and betahistine and were instructed to perform vestibular exercises; however, the control group did not receive a placebo. In the post-intervention analysis, 88% of the flunarizine group compared to 52% of the control group reported having 'low vertigo frequency' (2–3 attacks or less per 3 months) according to a unique 6-point Likert scale (P = 0.01), and 88% of the flunarizine group reported a 'marked improvement' compared to 61% of the control group, using another unique scale (P = 0.046). However, the study did not report outcome measures at baseline, and multiple scale points were grouped together arbitrarily to determine 'low frequency' and 'marked improvement'; it was not clear whether adjustment to the significance level for multiple comparisons was made. There were no significant differences in headache measures between the two groups.

A single-blinded quasi-randomized study systematically allocated 75 participants to either flunarizine 10 mg daily, venlafaxine 37.5 mg daily, or sodium valproate 500 mg twice daily. In a before-and-after analysis of the flunarizine group, there were small improvements in subjective VAS vertigo severity (6.4–5.9, P = 0.03), and monthly vertigo frequency (5.0–4.2 attacks per month, P…).

---

### Vestibular migraine treatment: A comprehensive practical review [^116h3tnE]. Brain (2022). Low credibility.

Cinnarizine was examined in two studies:

- **First study**: This was a retrospective, uncontrolled before-and-after study involving 24 patients with vestibular migraine (VM) and 16 patients with migraine with brainstem aura. They were treated with 75 mg daily for 3 months, primarily focusing on headache outcomes. Baseline attack frequency was relatively low compared to other studies. For VM patients, mean monthly vertigo frequency improved from 3.37 to 0.42 attacks per month (P < 0.001), and monthly headache frequency improved from 3.92 to 0.75 attacks per month (P < 0.001). There was also a marked reduction in mean headache duration from 23.58 hours to 2.58 hours (P < 0.001), and severity decreased from 8 to 1 on a VAS 0–10 (P < 0.001).

- **Second study**: This was a prospective observational study that followed 22 patients given a combination of cinnarizine 20 mg and diphenhydramine 40 mg, twice daily every second month (i.e. 'month on, month off') for 6 months, along with dietary and lifestyle advice (not detailed). These patients were compared to a control group of 11 patients given dietary and lifestyle advice alone, without placebo. Patients had relatively mild disease, with mean vertigo and headache attack frequency less than once monthly at baseline, and patients receiving the study medication had more frequent attacks at baseline. The mean reduction in 6-monthly vertigo frequency was 3.2 attacks in the treatment group compared to 1.3 in the control group [mean difference (MD) 1.9, P = 0.143], and the mean reduction in 6-monthly headache frequency was 2.6 compared to 0.6 (MD 2.0, P = 0.10).

---

### Aurlumyn [^116wZuix]. U.S. Food and Drug Administration (2024). High credibility.

Advise patients that they may experience a fall in blood pressure with Aurlumyn, which may cause dizziness during drug administration. They should stand up slowly when getting out of a chair or bed.

---

### Levocetirizine dihydrochloride [^115EdYwg]. U.S. Food and Drug Administration (2019). Low credibility.

The effectiveness of levocetirizine dihydrochloride 1.25 mg once daily (for ages 6 months to 5 years) and 2.5 mg once daily (for ages 6 to 11 years) in treating symptoms of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria is supported by the extrapolated efficacy of levocetirizine dihydrochloride 5 mg once daily in patients aged 12 years and older. This is based on the pharmacokinetic comparison between adults and children.

Cross-study comparisons indicate that administering a 5 mg dose of levocetirizine dihydrochloride to pediatric patients aged 6 to 12 years with seasonal allergic rhinitis resulted in about twice the systemic exposure (AUC) observed when the same dose was administered to healthy adults. Therefore, in children aged 6 to 11 years, the recommended dose of 2.5 mg once daily should not be exceeded. In a population pharmacokinetics study, administering 1.25 mg once daily in children aged 6 months to 5 years resulted in systemic exposure comparable to 5 mg once daily in adults [see Dosage and Administration (2.2); Clinical Studies (14); and Clinical Pharmacology (12.3)].

Pediatric use for patients aged 6 months to 5 years is approved for UCB Inc.'s levocetirizine dihydrochloride product. However, due to UCB Inc.'s marketing exclusivity rights, this drug product is not labeled for use in these pediatric patients.

---

### Levocetirizine dihydrochloride [^114JCvaQ]. U.S. Food and Drug Administration (2019). High credibility.

The efficacy of levocetirizine dihydrochloride was evaluated in six randomized, placebo-controlled, double-blind clinical trials involving adult and adolescent patients aged 12 years and older with symptoms of seasonal or perennial allergic rhinitis.

- **Study design**:
	- Three dose-ranging trials lasted between 2 to 4 weeks.
	- One 2-week efficacy trial focused on patients with seasonal allergic rhinitis.
	- Two efficacy trials, lasting 6 weeks and 6 months respectively, targeted patients with perennial allergic rhinitis.

A total of 2412 patients participated (1068 males and 1344 females), including 265 adolescents aged 12 to 17 years. Efficacy was measured using a total symptom score. In five studies, patients recorded symptoms such as sneezing, rhinorrhea, nasal pruritus, and ocular pruritus. One study also included nasal congestion among the symptoms. Patients used a 0–3 categorical severity scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe) to record symptoms once daily in the evening, reflecting the prior 24-hour treatment period. One study required patients to record symptoms an hour before the next dose as well. The primary endpoint was the mean total symptom score averaged over the first week and over 2 weeks for seasonal allergic rhinitis trials, and over 4 weeks for perennial allergic rhinitis trials.

---

### EFNS guideline on the drug treatment of migraine — revised report of an EFNS task force [^112SxrFL]. European Journal of Neurology (2009). High credibility.

Regarding preventative measures for migraine, more specifically with respect to migraine prophylaxis, the EFNS 2009 guidelines recommend offering candesartan 16 mg or lisinopril 20 mg as a third choice for migraine prophylaxis.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^1129e9Zg]. The Cochrane Database of Systematic Reviews (2023). High credibility.

- **Summary of findings 1**: Beta-blockers compared to placebo for prophylaxis of vestibular migraine.

- **Summary of findings 2**: Calcium channel blockers compared to no intervention for prophylaxis of vestibular migraine.

---

### Vestibular migraine: The most frequent entity of episodic vertigo [^116SRFZQ]. Journal of Neurology (2016). Low credibility.

Flunarizine was tested for the treatment of migraine without aura and the treatment of vertigo in two large open-label post-marketing studies. In both conditions, flunarizine showed considerable efficacy compared to propranolol for migraine headache or betahistine for vertigo. However, both studies did not specifically include patients with vestibular migraine (VM) and thus the efficacy of flunarizine for this condition remains unproven.

The only randomized controlled trial from one tertiary academic center compared the effects of flunarizine in 48 VM patients over 12 weeks with those receiving 16 mg of betahistine and vestibular exercises. The flunarizine treatment decreased the frequency of vertiginous episodes (p = 0.010), and the severity of vertigo improved (p = 0.046). However, the frequency and severity of headache were not significantly different in the two treatment groups. Side effects of flunarizine included weight gain and somnolence.

A retrospective chart study evaluated the effects of flunarizine and propranolol in another 61 patients with VM. Flunarizine patients (n = 30) showed a 68% responder rate for VM symptoms (p < 0.001), while patients on propranolol (n = 31) had an improvement rate of 73% (p < 0.001).

---

### Functional gastrointestinal disorders in migrainous children: Efficacy of flunarizine [^116DWebV]. Cephalalgia (2006). Low credibility.

The aim of this study was to evaluate the prevalence of functional gastrointestinal disorders (FGIDs) in children with migraine headaches and the effects of flunarizine on gastrointestinal manifestations. We studied 50 migrainous children, with a mean age of 8.63 years. The clinical pattern and diagnosis of FGIDs were obtained from structured questionnaires. All subjects underwent measurement of total gastric emptying time (TGEt) using real-time ultrasonography of the gastric antrum at baseline (T0).

In the second part of the study, we evaluated 10 migrainous children, with a mean age of 9.8 years, who had associated FGIDs. In these 10 patients, repeated TGEt evaluations, together with a detailed symptom history, were conducted after 1 month (T1) and 2 months (T2) of treatment with flunarizine. Control groups comprised 10 migrainous children without FGIDs (mean age 9.2 years) and nine sex- and age-matched healthy children.

Gastrointestinal disorders were present in 70% of the patients. Migrainous children with FGIDs had significantly more prolonged TGEt than those without FGIDs (P < 0.01). Prior to therapy, all migrainous children with FGIDs experienced prolongation of TGEt compared with controls (P < 0.05). Patients on flunarizine exhibited a significant decrease in TGEt after both 1 month (P < 0.01) and 2 months (P = 0.002) of therapy. The mean frequency of abdominal pain per month was significantly reduced at T1 compared with T0 (P < 0.001). The mean frequency of vomiting per month was significantly decreased at T1 (P < 0.05) and even more so at T2 (P < 0.01). Finally, the mean frequency of headaches per month was significantly reduced.

---

### Calcium antagonists as an add-on therapy for drug-resistant epilepsy [^115isk85]. The Cochrane Database of Systematic Reviews (2013). High credibility.

This is an updated version of the original Cochrane review published in The Cochrane Library 2001, Issue 4. Nearly a third of people with epilepsy do not have their seizures controlled with treatments. Continuous attempts have been made to find new antiepileptic drugs based on increasing knowledge of the cellular and molecular biology involved in the genesis of epilepsy and seizures. Therefore, calcium antagonists that can alter the effects of calcium on brain cells have been investigated for their effect on epileptic seizures.

- **Objectives**: To evaluate the effects of calcium antagonists when used as an add-on therapy for people with drug-resistant epilepsy.

- **Search methods**: We searched the Cochrane Epilepsy Group Specialized Register (29 January 2013), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 12), MEDLINE (1948 to 29 January 2013), and SCOPUS (all years to 29 January 2013).

- **Selection criteria**: Randomized placebo-controlled or active-controlled add-on trials of any calcium antagonist in people with drug-resistant epilepsy.

- **Data collection and analysis**: Two review authors (MH and JP) independently selected trials for inclusion and extracted data. Outcomes investigated included a 50% or greater reduction in seizure frequency, treatment withdrawal, adverse effects, cognition, and quality of life. Analyses were by intention to treat.

- **Main results**: Eleven trials were included with a total of 424 participants, one parallel-group and seven cross-over trials of flunarizine, two cross-over trials of nimodipine, and one additional trial not specified.

---

### Systemic pharmacological interventions for Ménière's disease [^115kT9Vs]. The Cochrane Database of Systematic Reviews (2023). High credibility.

How the intervention might work:

As the underlying cause of Ménière's disease is poorly understood, so too are the ways in which the interventions may work.

Several classes of histamine receptors are found within the inner ear. Betahistine is a histamine H₃ antagonist and a weak H₁ agonist. Betahistine is thought to increase blood flow in the inner ear, which may impact endolymphatic fluid pressure. It may also have a direct effect on the vestibular nerve to reduce nerve cell firing and the frequency of vertigo attacks. Other antihistamines, such as cinnarizine or dimenhydrinate, may also be used.

Diuretics are utilized with the intention of reducing the volume of endolymph and the pressure in the endolymphatic system by altering the electrolyte balance and promoting water loss through the kidneys. The mechanism of action varies depending on the class of drug and includes:

- **Inhibition of renal carbonic anhydrase**: This occurs in the proximal tubules, resulting in increased bicarbonate and sodium excretion (carbonic anhydrase inhibitors).

- **Inhibition of chloride transport**: This occurs in the ascending loop (loop diuretics).

- **Inhibition of sodium and calcium resorption**: This occurs in the distal tubules (thiazides).

- **Alteration of electrolyte transport**: This occurs in the distal tubules and collecting ducts (potassium-sparing diuretics).

As noted above, it has been suggested that some cases of Ménière's disease may be caused by a viral infection. Consequently, there has been interest in the use of antiviral medication, such as aciclovir.

---

### Relpax [^116mAxf5]. U.S. Food and Drug Administration (2024). High credibility.

Adverse reactions are described in various sections of the prescribing information: myocardial ischemia and myocardial infarction, Prinzmetal's angina [see Warnings and Precautions (5.2)]; arrhythmias [see Warnings and Precautions (5.3)]; chest, throat, neck, and/or jaw pain/tightness/pressure [see Warnings and Precautions (5.4)]; cerebrovascular events [see Warnings and Precautions (5.4)]; other vasospasm reactions [see Warnings and Precautions (5.5)]; medication overuse headache [see Warnings and Precautions (5.6)]; serotonin syndrome [see Warnings and Precautions (5.7)]; increase in blood pressure [see Warnings and Precautions (5.8)]; hypersensitivity reactions [see Contraindications (4) and Warnings and Precautions (5.9)].

- **Clinical trials experience**: Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Among 4,597 patients who treated the first migraine headache with Relpax in short-term placebo-controlled trials, the most common adverse reactions reported were asthenia, nausea, dizziness, and somnolence. These reactions appear to be dose-related. In long-term open-label studies where patients were allowed to treat multiple migraine attacks for up to 1 year, 128 (8.3%) out of 1,544 patients discontinued treatment due to adverse reactions.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^114BKW5a]. The Cochrane Database of Systematic Reviews (2023). High credibility.

The authors of both studies reported on some of our pre-specified adverse effects of interest. As noted in the data synthesis, we used the Peto odds ratio for these analyses due to the low event rates. The Peto odds ratio for drowsiness in those receiving flunarizine was 3.85 (95% CI 0.73 to 20.26; 2 studies; 71 participants; I² = 0%; very low-certainty evidence; Analysis 2.5). The Peto odds ratio for weight gain in those receiving flunarizine was 2.58 (95% CI 0.35 to 18.94; 2 studies; 71 participants; I² = 0%; very low-certainty evidence; Analysis 2.5).

---

### Oral cinnarizine for the treatment of COVID-19-associated chilblain-like lesions: An old drug for a new disease [^115Sxnd4]. Dermatologic Therapy (2022). Low credibility.

During the SARS-CoV-2 pandemic, an outbreak of chilblain-like lesions was observed, although the relationship with the virus infection is still debated. We report the positive outcomes in 12 patients with chilblain lesions following the use of oral cinnarizine, a piperazine derivative with various pharmacological properties, including antihistaminic and calcium channel blocking activities.

---

### Amitiza [^116kKDqb]. U.S. Food and Drug Administration (2024). High credibility.

The primary efficacy analysis was a comparison of the proportion of "overall responders" in each arm. A patient was considered an "overall responder" if the criteria for being designated a "monthly responder" were met in at least 2 of the 3 months on study. A "monthly responder" was defined as a patient who had reported being "significantly relieved" for at least 2 weeks of the month or at least "moderately relieved" in all 4 weeks of that month. During each monthly evaluation period, patients reporting "moderately worse" or "significantly worse" relief, an increase in rescue medication use, or those who discontinued due to lack of efficacy, were deemed non-responders.

The percentage of patients in Study 1 qualifying as an "overall responder" was 14% in the group receiving Amitiza 8 mcg twice daily compared to 8% of patients receiving placebo twice daily. In Study 2, 12% of patients in the Amitiza 8 mcg group were "overall responders" versus 6% of patients in the placebo group. In both studies, the treatment differences between the placebo and Amitiza groups were statistically significant.

- **Results in men**: The two randomized, placebo-controlled, double-blinded studies comprised 97 (8%) male patients, which is insufficient to determine whether men with IBS-C respond differently to Amitiza compared to women.

During a 4-week randomized withdrawal period following Study 1, patients who received Amitiza during the 12-week treatment period were re-randomized to receive either placebo or to continue treatment with Amitiza.

---

### Permanent non-progressive cinnarizine and flunarizine-induced parkinsonism: An under-recognized tardive syndrome in the elderly [^111z98zC]. Journal of the Neurological Sciences (2023). Low credibility.

Secondary parkinsonism induced by exposure to dopamine (DA) receptor antagonists, such as first and second generation antipsychotics, DA storage depleters, calcium channel blockers, and substituted benzamides, is traditionally believed to be completely reversible in most patients following withdrawal of the offending drug, even though there may be a variable time delay. The lack of recovery or initial full recovery with subsequent development of progressive parkinsonism has been regarded as a result of an underlying subclinical degenerative process like Parkinson's disease (PD) unmasked by the inducing drug.

These well-recognized clinical outcomes of drug-induced parkinsonism (DIP) have disregarded the existence of another outcome characterized by permanent non-progressive parkinsonism. This syndrome may fulfill the criteria of tardive parkinsonism, a controversial entity currently referred to as a persistent condition without indication of its long-term course and clinical features.

On reviewing the published literature on DIP, we have identified two prospective long-term follow-up studies of elderly patients in which parkinsonism induced by the calcium channel antagonists cinnarizine and flunarizine became permanent and non-progressive following drug discontinuation in a non-negligible proportion of patients. This is consistent with the clinical concept of a true tardive syndrome, according to currently accepted criteria.

The authors hypothesize that the development of tardive parkinsonism might be due to a neurotoxic effect of the pharmacodynamic properties of the calcium channel blockers.

---

### World guidelines for falls prevention and management for older adults: a global initiative [^112DbPFE]. Age and Ageing (2022). High credibility.

Regarding preventative measures for falls in the elderly, particularly in relation to medication review, the WFG 2022 guidelines recommend conducting a medication review and deprescribing fall risk-increasing drugs as part of multidomain fall prevention interventions. Use a validated, structured screening and assessment tool to identify fall risk-increasing drugs when performing a general medication review or a medication review specifically targeted at fall prevention.

---

### The diagnosis and management of acute and chronic urticaria: 2014 update [^112DXkTm]. The Journal of Allergy and Clinical Immunology (2014). High credibility.

Regarding medical management for acute urticaria, specifically with respect to antihistamines, the AAAAI/ACAAI 2014 guidelines recommend administering antihistamines as first-line therapy in patients with acute urticaria and angioedema.

---

### Misconceptions and facts about beta-blockers [^113tw7oQ]. The American Journal of Medicine (2019). Low credibility.

Beta-blockers are commonly used medications, traditionally considered "cardioprotective". Their clinical use appears to be more widespread than the available evidence supporting their role in cardioprotection. Beta-blockers counteract neurohumoral activation in heart failure with reduced ejection fraction and offer both symptomatic improvement and reduction in adverse events. However, the use of beta-blockers in uncomplicated hypertension results in suboptimal outcomes compared to the established first-line antihypertensive agents. Providers at all levels should be familiar with common misconceptions regarding beta-blocker use in routine clinical practice.

---

### Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology [^114QLe2d]. Journal of Psychopharmacology (2020). High credibility.

Regarding medical management for schizophrenia, specifically concerning maintenance therapy, the BAP 2020 guidelines recommend reviewing the need for continued antipsychotic medication after at least two years of maintained remission following a single episode (proposed as stage IIa schizophrenia), unless low-grade psychotic symptoms suggest that the psychotic process has not fully abated (stage IIc).

---

### Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily [^1124P9dC]. Cephalalgia (2002). Low credibility.

This was a phase-IV double-blind equivalence trial designed to assess the efficacy and tolerability of two doses of flunarizine (10 mg o.d. = FLU 10 mg and 5 mg o.d. = FLU 5 mg) in the prophylaxis of migraine, in comparison with slow-release propranolol (160 mg o.d.). A total of 808 subjects were treated over a treatment period of 16 weeks. A total of 142 subjects discontinued the trial prematurely, mainly because of adverse events (n = 58).

The mean attack frequency during the double-blind period was 2.0 for the FLU 5 mg group, 1.9 for the FLU 10 mg group, and 1.9 for the propranolol group. In the last 28 days of the double-blind period, the mean attack frequency was 1.8 for FLU 5 mg, 1.6 for FLU 10 mg, and 1.7 for propranolol. Both flunarizine groups were at least as effective as propranolol (P < 0.001 in a one-sided test).

The percentage of responders — defined as subjects for whom attack frequency decreased by at least 50% compared to the run-in phase — in the last 28 days of the double-blind period was 46% (118/259) for FLU 5 mg, 53% (141/264) for FLU 10 mg, and 48% (125/258) for propranolol. Statistical analysis showed that FLU 10 mg is at least as effective as propranolol (P < 0.001) and indicated a trend for the noninferiority of FLU 5 mg to propranolol (P = 0.053). No statistically significant differences between the treatment groups were found for any secondary parameters.

Overall, 190 subjects reported one or more adverse events during the run-in phase: 54 (20.5%) in the FLU 5 mg group, 76 (27.7%) in the FLU 10 mg group, and 60 (22.3%) in the propranolol group.

---

### Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study [^112qunnF]. Journal of Glaucoma (2011). Low credibility.

The aim of this study was to evaluate the efficacy and tolerability of flunarizine, a nonselective calcium channel blocker, on intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OH).

- **Design**: The study was a randomized, placebo-controlled, double-blind, cross-over phase II trial.

- **Methods**: Ten patients diagnosed with bilateral OAG or OH were included, with each patient serving as their own control. On the first study visit, one drop of either 0.05% flunarizine or placebo was applied in the study eye. Patients were followed up over 6 hours (0, 15, 30, and 60 minutes, and 2, 3, 4, and 6 hours) for vital signs, slit lamp examination, corneal fluorescein staining, and IOP. After a wash-out period of 4 weeks, one drop of either placebo or flunarizine was applied in the same eye, and patients were followed up for another 6 hours.

- **Results**: The flunarizine group showed a statistically significant decrease from baseline at T2, T3, T4, and T6 hours (P = 0.01, P = 0.03, P = 0.01, and P = 0.03, respectively). No significant difference in IOP decrease from baseline (P > 0.06) was observed between the two groups. There was no statistically significant difference in the following parameters: limbal hyperemia, bulbar or palpebral conjunctival hyperemia, corneal staining with fluorescein, best-corrected visual acuity, comfort of eye drops, and vital signs.

- **Conclusions**: The absence of a statistically significant difference in IOP reduction between the two groups may be due to the small number of patients included. However, a single dose of 0.05% flunarizine significantly reduced IOP when compared with baseline.

---

### SPL drug information for chlorcyclizine hydrochloride [^111goBXG]. U.S. Food and Drug Administration. High credibility.

Warnings and precautions regarding the use of chlorcyclizine hydrochloride PO (also known as Ahist):

- **Cardiac arrhythmias, hypertension**: Use extreme caution with pre-existing cardiovascular conditions. Monitor cardiovascular parameters closely in patients with cardiovascular disorders. Assess the severity, manage symptoms, and consult a cardiologist for appropriate intervention if needed.

- **CNS depression**: Use caution when taking other CNS depressants like alcohol, sedatives, or opioids. Adhere to recommended dosages and avoid concurrent use of other CNS depressants. If adverse effects occur, discontinue the medication, provide supportive care, and closely monitor the patient's mental status and vital signs.

- **Dry mouth, blurred vision, constipation, urinary retention**: Use caution with risk factors for anticholinergic effects. Monitor patients closely, especially those at higher risk, for anticholinergic adverse effects. Discontinue the medication, provide supportive care, and consider appropriate antidotal treatment if necessary.

---

### Reducing stillbirths: Prevention and management of medical disorders and infections during pregnancy [^112KJTp5]. BMC Pregnancy and Childbirth (2009). Low credibility.

- **Impact of anti-hypertensive drugs on stillbirth and perinatal mortality**: In another Cochrane review comparing the impact of calcium channel blockers to any other tocolytic agent in inhibiting pre-term labor, King et al. (2003) found no statistically significant difference in PMR (10 trials; N = 810 pregnant women, RR = 1.65, 95% CI: 0.74–3.64) [LOE: 1+] (Additional file 6). Similarly, Say et al. (1996) compared flunarizine vs. no treatment in pregnant women either at high risk or with suspected impaired fetal growth and found a large but non-significant reduction in PMR (OR = 0.14, 95% CI: 0.00–6.82) [LOE: 1+] (Additional file 7). Other Cochrane reviews of the effect of hypertensive treatments on pregnancy outcomes are in progress.

- **Australian study on anti-hypertensive drugs**: Among other studies, an RCT in an Australian tertiary referral maternity hospital by Hennessy et al. compared different anti-hypertensive drugs in hypertensive women (N = 124) and reported three perinatal deaths in the group given IV hydralazine (5 mg doses) compared to one perinatal death in the group given mini-bolus diazoxide (15 mg doses), but the study was too small for the results to reach statistical significance [LOE: 1+].

- **Meta-analysis on nitric oxide and pre-eclampsia**: Another meta-analysis by Meher et al. assessed the impact of nitric oxide in preventing pre-eclampsia (N = 4 RCTs) and computed a non-significant decrease in risk of perinatal and neonatal mortality combined compared to untreated controls (RR = 0.25, 95% CI: 0.03–2.34 [NS]) [LOE: 1+] (Additional file 8).

---

### Guideline on the investigation and management of acute transfusion reactions [^114fFKoE]. British Journal of Haematology (2023). High credibility.

Regarding medical management for acute transfusion reactions, more specifically with respect to antihistamines, BSH 2023 guidelines recommend considering slowing the transfusion and administering an antihistamine in patients with mild allergic reactions.

---

### EFNS guidelines for the diagnosis and management of Alzheimer's disease [^113Lw1JM]. European Journal of Neurology (2010). High credibility.

Regarding the medical management of Alzheimer's disease, particularly with cholinesterase inhibitors, the EFNS 2010 guidelines recommend considering the administration of cholinesterase inhibitors such as donepezil, galantamine, or rivastigmine to patients at the time of diagnosis. This recommendation is based on the expected therapeutic benefits and potential safety issues. Benefits for both cognitive and non-cognitive symptoms have been demonstrated in patients with mild, moderate, and severe stages of the disease.

---

### New approaches to the management of peripheral vertigo: Efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study [^113AfTd1]. Otology & Neurotology (2002). Low credibility.

To evaluate the efficacy and safety profile, a study was conducted using 30-mg nimodipine oral tablets taken three times per day (one tablet with breakfast, one with lunch, and one with dinner) or 150-mg cinnarizine verum oral capsules taken once daily with dinner for 12 weeks. This comparative, double-blind, multinational pilot study was set in a tertiary referral center. Of the 221 patients who met the study criteria, 181 adult patients completed the study. This group consisted of 135 women and 46 men, aged between 20 and 80 years.

Two calcium antagonists were used to treat vertigo: nimodipine for 89 patients and cinnarizine for 92 patients. All patients adhered to the same dosage regimen until completing 12 weeks of treatment. Patients were evaluated at 2- and 4-week intervals, with an additional evaluation at Week 14 to determine vertigo recurrence in the posttreatment period.

The main outcome measures included the vertigo severity index, assessing the response by counting vertigo episodes during a specific period, with each episode weighted according to its intensity. Results showed that nimodipine treatment decreased the incidence of moderate vertigo episodes by 78.8% and severe vertigo episodes by 85.0%. Cinnarizine treatment resulted in a 65.8% decrease in moderate vertigo episodes and an 89.8% reduction in severe episodes. Both nimodipine and cinnarizine exhibited similar safety profiles. Only two patients withdrew from the study due to adverse events potentially related to the study drug.

---

### Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis [^116GfePb]. Pain (2019). High credibility.

Based on a few clinical trials, flunarizine is considered a first-line prophylactic treatment for migraine in several guidelines. In this meta-analysis, we examined the pooled evidence for its effectiveness, tolerability, and safety. Prospective randomized controlled trials of flunarizine as a prophylaxis against migraine were identified from a systematic literature search, and the risk of bias was assessed for all included studies.

The reduction in mean attack frequency was estimated by calculating the mean difference (MD), and a series of secondary outcomes, including adverse events (AEs), were also analyzed. The database search yielded 879 unique records, and twenty-five studies were included in data synthesis. We scored 31/175 risk of bias items as "high", with attrition as the most frequent bias.

A pooled analysis estimated that flunarizine reduces the headache frequency by 0.4 attacks per 4 weeks compared with placebo: five trials with 249 participants (MD -0.44; 95% confidence interval -0.61 to -0.26). Analysis also revealed that the effectiveness of flunarizine prophylaxis is comparable with that of propranolol: seven trials with 1151 participants (MD -0.08; 95% confidence interval -0.34 to 0.18). Flunarizine also seems to be effective in children. The most frequent AEs were sedation and weight increase.

The meta-analyses were robust and homogeneous, although several of the included trials potentially suffered from a high risk of bias. Unfortunately, reporting of AEs was inconsistent and limited. In conclusion, the pooled analysis of data from partially outdated trials shows that 10-mg flunarizine per day is effective for migraine prophylaxis.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^111rHC9h]. The Cochrane Database of Systematic Reviews (2023). High credibility.

We included the following types of interventions: beta-blockers, calcium channel blockers, antiepileptics, antidepressants, diuretics, monoclonal antibodies to CGRP or its receptor, botulinum toxin, and hormonal modification.

The main comparisons were planned to be: beta-blockers versus placebo/no treatment; calcium channel blockers versus placebo/no treatment; antiepileptics versus placebo/no treatment; antidepressants versus placebo/no treatment; diuretics versus placebo/no treatment; monoclonal antibodies to CGRP or its receptor versus placebo/no treatment; botulinum toxin versus placebo/no treatment; and hormonal modification versus placebo/no treatment.

- **Concomitant treatments**: There were no limits on the type of concomitant treatments used, provided these were used equally in each arm of the study. We planned to pool studies that included concomitant treatments with those where participants did not receive such treatment, conducting subgroup analysis to determine whether the effect estimates may differ in those receiving additional treatment.

- **Types of outcome measures**: We assessed outcomes at the following time points: 6 to 12 months. The exception was for adverse event data, for which we used the longest period of follow-up.

We searched the COMET database for existing core outcome sets relevant to vestibular migraine and vertigo but were unable to find any published core outcome sets. Therefore, we conducted a survey of individuals with experience in, or interest in, balance disorders to help identify outcome measures.

---

### Zomig [^112ffMPC]. U.S. Food and Drug Administration (2024). High credibility.

Do not take ZOMIG if you:

- **Have heart disease or a history of heart disease**: Individuals with these conditions are at increased risk.
- **Have uncontrolled high blood pressure**: This medication may exacerbate the condition.
- **Have hemiplegic or basilar migraine**: If uncertain about these conditions, consult your doctor.
- **Have had a stroke or problems with your blood circulation**: This can lead to serious complications.
- **Have serious liver problems**: Liver issues can affect how the drug is processed in the body.
- **Have taken specific medications in the last 24 hours**: These include:
	- Triptans such as almotriptan (AXERT®), eletriptan (RELPAX®), frovatriptan (FROVA®), naratriptan (AMERGE®), rizatriptan (MAXALT®), sumatriptan (IMITREX®), sumatriptan/naproxen (TREXIMET).
	- Ergotamines like BELLERGAL-S®, CAFERGOT®, ERGOMAR®, WIGRAINE®.
	- Dihydroergotamine like D.H.E. 45® or MIGRANAL®.
	- Methysergide (SANSERT®). These medications have side effects similar to ZOMIG.
- **Have taken monoamine oxidase (MAO) inhibitors**: Such as phenelzine sulfate (NARDIL®) or tranylcypromine sulfate (PARNATE®) within the last 2 weeks.
- **Are allergic to ZOMIG or any of its ingredients**: The active ingredient is zolmitriptan, and details about inactive ingredients can be found at the end of the leaflet.

Take ZOMIG exactly as directed by your doctor. They will determine the appropriate dosage and timing. Safely dispose of any unused tablets or pieces of tablets removed from blister packaging. If your headache returns after the first dose, you may take a second dose at least 2 hours after the first. However, if the first dose does not alleviate your symptoms, consult your doctor before taking another. Do not exceed the recommended dosage.

---

### Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society [^114tPpky]. Neurology (2012). High credibility.

Regarding preventative measures for migraines, and specifically migraine prophylaxis, the American Academy of Neurology (AAN) 2012 guidelines recommend that there is insufficient evidence to support for, or against the use of nicardipine, nifedipine, nimodipine, or verapamil for migraine prophylaxis.

---

### The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria [^111ivgw2]. Allergy (2022). High credibility.

Regarding medical management for chronic urticaria, specifically with respect to cyclosporin, APAAACI/EAACI/EDF/GA²LEN 2022 guidelines recommend considering offering cyclosporin to patients with chronic urticaria unresponsive to high doses of second-generation H₁RAs and omalizumab.

---

### Drugs for the treatment of nausea and vomiting in adults in the emergency department setting [^114HVDuz]. The Cochrane Database of Systematic Reviews (2015). Low credibility.

Nausea and vomiting is a common and distressing presenting complaint in emergency departments (EDs). The aetiology of nausea and vomiting in EDs is diverse, and drugs are commonly prescribed. There is currently no consensus on the optimum drug treatment of nausea and vomiting in the adult ED setting.

- **Objectives**: To provide evidence of the efficacy and safety of antiemetic medications in the management of nausea and vomiting in the adult ED setting.

- **Search methods**: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 8), MEDLINE (OvidSP) (January 1966 to August 2014), EMBASE (OvidSP) (January 1980 to August 2014), and ISI Web of Science (January 1955 to August 2014). We also searched relevant clinical trial registries and conference proceedings.

- **Selection criteria**: We included randomized controlled trials (RCTs) of any drug in the treatment of nausea and vomiting in adults in the ED. Study eligibility was not restricted by language or publication status.

- **Data collection and analysis**: Two review authors independently performed study selection, data extraction, and assessment of risk of bias in included studies. We contacted authors of studies to obtain missing information if required.

- **Main results**: We included eight trials involving 952 participants, of which 64% were women. Included trials were generally of adequate quality, with six trials at low risk of bias and two trials at high risk of bias. Three trials with 518 participants compared five different drugs with placebo; all reported the primary outcome as…

---

### Risperdal [^1116BuVQ]. U.S. Food and Drug Administration (2025). High credibility.

In a longer-term trial, 365 adult outpatients, predominantly meeting DSM-IV criteria for schizophrenia and clinically stable for at least four weeks on an antipsychotic medication, were randomized to receive Risperdal (2–8 mg/day) or an active comparator. The observation period lasted for one to two years to monitor relapse rates. Patients receiving Risperdal experienced a significantly longer time to relapse compared to those receiving the active comparator.

---

### Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society [^111WVyAA]. Neurology (2012). High credibility.

Regarding preventative measures for migraines, specifically in relation to migraine prophylaxis, the AAN 2012 guidelines recommend avoiding the use of clonazepam and oxcarbazepine for migraine prophylaxis.

---

### Evidence update for the treatment of anaphylaxis [^116yvLpA]. Resuscitation (2021). Low credibility.

Rationale

There is no RCT or quasi-RCT evidence to support the use of antihistamines in treating anaphylaxis. Antihistamines do not lead to resolution of respiratory or cardiovascular symptoms of anaphylaxis, or improve survival.H₁-antihistamines cause sedation which can confound symptoms of anaphylaxis, and if given by rapid intravenous bolus may precipitate hypotension. Recent guidelines relegate antihistamines to a second or third-line intervention; most express a concern that their use can delay the administration of both initial and subsequent doses of adrenaline. This is based on a large number of datasets which report that the majority of patients presenting with anaphylaxis to Emergency Departments are treated with antihistamines, yet only a minority receive adrenaline – despite an increasing emphasis on adrenaline as the first-line intervention in international guidelines. In a large, national prospective registry (Cross-Canada Anaphylaxis Registry, C-CARE), 3498 cases of anaphylaxis were enrolled over a 6 year period; prehospital antihistamine use was associated with a lower rate of administration of > 1 adrenaline dose (adjusted OR 0.61; 95% CI 0.44–0.85), but not other outcomes (hospitalisation/intensive care, intravenous fluids). Moreover, this finding was not robust at sensitivity analyses: excluding less severe reactions, prehospital antihistamine did not affect outcomes; unfortunately, the authors did not assess the impact on > 2 doses of adrenaline being given. An association between pre-hospital antihistamine use and delayed presentation to healthcare facili

---

### SIGN 155 pharmacological management of migraine: A national clinical guideline [^112wGbsL]. SIGN (2023). High credibility.

Regarding preventative measures for migraines, specifically concerning migraine prophylaxis, the SIGN 2023 guidelines suggest offering candesartan at a dose of 16 mg daily as a prophylactic therapy for patients with episodic or chronic migraine.

---

### Systemic pharmacological interventions for Ménière's disease [^117Pcm9h]. The Cochrane Database of Systematic Reviews (2023). High credibility.

There were also differences in the types of studies included in some existing reviews on diuretics. Three reviews included cross-over trials (Claes 1997; Claes 2000; Rosenbaum 2018). Another included observational studies, as well as RCTs that compared diuretics to other active treatments, cross-over trials, and those with a short duration of follow-up (Crowson 2016). As with this review, Rosenbaum (2018) concludes that the evidence for the efficacy of diuretics is very low certainty. Crowson (2016), however, suggests that the evidence supports the use of diuretics, but acknowledges that this is "low-level evidence" (predominantly from observational studies). The two reviews by Claes and Van de Heyning conclude that diuretics have proven efficacy in the long-term control of vertigo, although this conclusion is only based on the inclusion of two cross-over trials of diuretics (Claes 1997; Claes 2000).

Two previous reviews did not identify any studies for inclusion, as they were published before the two included studies in this review (Burgess 2006; James 2007).

---

### Night-time sedating H₁-antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial [^113mEZGv]. The British Journal of Dermatology (2014). High credibility.

Many physicians believe that the most effective way to treat chronic urticaria is to take a nonsedating second-generation H1-antihistamine in the morning and a sedating first-generation H1-antihistamine, usually hydroxyzine, at night to enhance sleep. But is this belief well founded?

- **Objectives**: To test this belief by comparing the effectiveness and prevalence of unwanted sedative effects when treating patients with chronic spontaneous urticaria (CSU) with levocetirizine 15 mg daily plus hydroxyzine 50 mg at night (levocetirizine plus hydroxyzine) vs. levocetirizine 20 mg daily (levocetirizine monotherapy).

- **Methods**: In this randomized, double-blind, cross-over study, 24 patients with difficult-to-treat CSU took levocetirizine plus hydroxyzine or levocetirizine monotherapy for periods of 5 days each. At the end of each treatment period, assessments were made of quality of life (Chronic Urticaria Quality of Life Questionnaire, CU-Q2oL), severity of urticaria symptoms (Urticaria Activity Score, UAS), sleep disturbance during the night, and daytime somnolence.

- **Results**: Both treatments significantly decreased UAS, night-time sleep disturbances, and CU-Q2oL scores (P < 0.001) without significant differences between the two. Compared with baseline, daytime somnolence was significantly reduced by levocetirizine monotherapy (P = 0.006) but not by levocetirizine plus hydroxyzine (P = 0.218). Direct comparison of the two treatment modalities in terms of daytime somnolence favored levocetirizine monotherapy (P = 0.026).

The widespread belief that sle

---

### Dimenhydrinate [^113bYL7B]. U.S. Food and Drug Administration (2025). High credibility.

Dimenhydrinate injection, USP, is indicated for the prevention and treatment of nausea, vomiting, or vertigo associated with motion sickness.

---

### Duavee [^111TBEkT]. U.S. Food and Drug Administration (2025). High credibility.

What are the possible side effects of Duavee?

Side effects are grouped by how serious they are and how often they occur during treatment.

- **Serious side effects include**:
	- **Cardiovascular and blood-related**: Blood clots, stroke, heart attack, high blood pressure, increased fats in your blood.
	- **Cancer-related**: Cancer of the lining of the uterus, breast cancer, cancer of the ovary.
	- **Neurological and sensory**: Dementia, loss of vision.
	- **Organ and metabolic issues**: Gallbladder problems, liver problems, thyroid problems, low calcium, fluid retention.
	- **Allergic reactions and other conditions**: Swelling of your mouth or tongue, worsening of other medical conditions such as asthma, diabetes, epilepsy, migraines, a genetic condition called porphyria, lupus, and liver problems.

	- Call your healthcare provider right away if you experience any of the following warning signs or any other unusual symptoms that concern you: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden severe headaches, or severe pain in your chest or legs with or without shortness of breath, weakness, and fatigue.

- **Less serious, but common side effects include**: Muscle spasms, nausea, diarrhea, upset stomach, abdominal pain, throat pain, dizziness, neck pain.

These are not all the possible side effects of Duavee. For more information, contact your healthcare provider or pharmacist. Inform your healthcare provider if you experience any bothersome or persistent side effects.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1–800-FDA-1088.

---

### Calcium antagonists as an add-on therapy for drug-resistant epilepsy [^117BPjd7]. The Cochrane Database of Systematic Reviews (2001). Low credibility.

As up to 30% of patients with epilepsy do not have their seizures controlled with treatments, there have been continuous attempts to find new antiepileptic drugs based on increasing knowledge of cellular and molecular biology involved in the genesis of epilepsy and seizures. Calcium has been established to play a major role in seizure occurrence; thus, calcium antagonists that can alter the effects of calcium on brain cells have been investigated for their effect on epileptic seizures.

- **Objectives**: To evaluate the effects of calcium antagonists on seizures, side effects, quality of life, and cognition when used as add-on therapy for patients with drug-resistant epilepsy.

- **Search strategy**: We searched MEDLINE from 1966 to 2000 and the Cochrane Epilepsy Group trials register, and the Cochrane Controlled Trials Register (The Cochrane Library Issue 1, 2001).

- **Selection criteria**: Randomized placebo-controlled add-on trials of any calcium antagonists in patients with drug-resistant epilepsy.

- **Data collection and analysis**: Two reviewers independently selected trials for inclusion and extracted data. Outcomes were: (a) 50% or greater reduction in seizure frequency; (b) treatment withdrawal (any reason); (c) side effects. For crossover trials, the first treatment period was treated as a parallel trial. Analyses were by intention to treat. Due to problems acquiring the data needed from crossover trials, overall results from these trials were summarized in tables.

- **Main results**: Eleven trials were included. One parallel and seven crossover trials of flunarizine, two cross.

---

### Flunarizine for headache prophylaxis in children with Sturge-Weber syndrome [^111Q57Ex]. Pediatric Neurology (2019). Low credibility.

Children with Sturge-Weber syndrome can experience severe headaches with or without transient hemiparesis. Flunarizine, a calcium antagonist, has been used for migraine. This study reviews the experience with flunarizine for headaches in a cohort of children at a national center for Sturge-Weber syndrome, reporting its efficacy and adverse effects in this population.

- **Methods**: We collected data from health care professionals' documentation on headache severity, frequency, and duration before and during flunarizine treatment in 20 children with Sturge-Weber syndrome. Adverse effects reported during flunarizine treatment were collated. The Wilcoxon signed rank test was used to determine the significance of pre- versus post-treatment effects.

- **Results**: Flunarizine was used for headache alone in 13 cases or for mixed migrainous episodes and vascular events in 7 cases. The median duration of treatment was 145 days (range 43 to 1864 days). Flunarizine reduced headache severity (z = -3.354, P = 0.001), monthly frequency (z = -2.585, P = 0.01), and duration (z = -2.549, P = 0.01). Flunarizine was discontinued due to intolerable adverse effects in a minority (2 cases). Sedation and weight gain were the most common side effects. There were no reports of behavior change or extrapyramidal features.

- **Conclusions**: The most effective management for headaches in patients with Sturge-Weber syndrome has not been established. This retrospective observational study found the benefit of flunarizine prophylaxis on headache severity, frequency, and duration in children with Sturge-Weber syndrome without severe side effects.

---

### SIGN 155 pharmacological management of migraine: A national clinical guideline [^115NeS9h]. SIGN (2023). High credibility.

Regarding preventative measures for migraine, specifically concerning migraine prophylaxis, the SIGN 2023 guidelines recommend offering erenumab, fremanezumab, or galcanezumab as prophylactic therapy in patients with chronic migraine. This recommendation holds where medication overuse has been addressed and patients have not benefited from appropriate trials of three or more oral migraine prophylactic treatments.

---

### Soaanz [^112thWKZ]. U.S. Food and Drug Administration (2024). High credibility.

Advise patients receiving Soaanz that lightheadedness can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. Patients should be told that if syncope occurs, Soaanz should be discontinued until the physician has been consulted.

All patients should be cautioned that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope [see Warnings and Precautions (5.1)].

- **Non-steroidal anti-inflammatory drugs (NSAID)**: Advise patients to discuss with their physician before taking NSAID medications concomitantly [see Drug Interactions (7.1)].

---

### Calcium antagonists for acute ischemic stroke [^111hmxGr]. The Cochrane Database of Systematic Reviews (2019). Low credibility.

The sudden loss of blood supply in ischemic stroke is associated with an increase of calcium ions within neurons. Inhibiting this increase could protect neurons and might reduce neurological impairment, disability, and handicap after stroke.

- **Objective**: To assess the effects of calcium antagonists for reducing the risk of death or dependency after acute ischemic stroke. We investigated the influence of different drugs, dosages, routes of administration, time intervals after stroke, and trial design on the outcomes.

- **Search methods**: The evidence is up to 6 February 2018. We searched the Cochrane Stroke Group Trials Register (6 February 2018), Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 2), MEDLINE Ovid (1950 to 6 February 2018), Embase Ovid (1980 to 6 February 2018), and four Chinese databases (6 February 2018): Chinese Biological Medicine Database (CBM-disc), China National Knowledge Infrastructure (CNKI), Chinese Scientific Periodical Database of VIP Information, and Wanfang Data. We also searched the following trials registries: ClinicalTrials.gov, EU Clinical Trials Register, Stroke Trials Registry, ISRCTN registry, WHO International Clinical Trials Registry Platform, and Chinese Clinical Trial Registry, and we contacted trialists and researchers.

- **Selection criteria**: Randomized controlled trials comparing a calcium antagonist versus control in people with acute ischemic stroke.

- **Data collection and analysis**: Two review authors independently selected trials, extracted data, assessed risk of bias, and applied the GRADE approach.

---

### A comparative study on prophylactic efficacy of cinnarizine and amitriptyline in childhood migraine: A randomized double-blind clinical trial [^116t5PKf]. Cephalalgia (2024). Low credibility.

Pediatric migraine prophylaxis is indicated when headaches are frequent and/or disabling. We aimed to conduct a study to compare the efficacy of cinnarizine and amitriptyline in pediatric migraine prophylaxis.

- **Methods**: In a randomized, double-blind trial, patients aged 4–17 years with migraines who were eligible for prophylaxis were enrolled. The primary outcome was a reduction response rate of ≥ 50% with p = 0.005. No serious adverse events were observed.

- **Conclusions**: Both medications are effective in ameliorating migraine headaches and related disabilities. However, amitriptyline appears to be a preferable option over cinnarizine, given its faster onset of action, efficacy in reducing headache duration, and longer-lasting effects.

---

### Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys [^115cRBT6]. Journal of Glaucoma (2008). Low credibility.

To evaluate the effects of flunarizine, a nonselective calcium channel blocker, on intraocular pressure (IOP) in monkeys with laser-induced unilateral glaucoma and on aqueous humor dynamics in normal monkeys, a series of studies were conducted.

The IOP was measured before and hourly for 6 hours after the single-dose administration of 0.5%, 1%, or 2% flunarizine to the glaucomatous eye of eight monkeys with unilateral laser-induced glaucoma. In a separate multiple-dose study, 0.5% flunarizine was applied twice daily for 5 consecutive days to the glaucomatous eye of the same eight monkeys. IOP was measured at untreated baseline, after treatment with vehicle only, and on treatment days 1, 3, and 5. Tonographic outflow facility and fluorophotometric flow rates of aqueous humor were measured in seven normal monkeys before and after the fifth dose of twice-daily treatment with 0.5% flunarizine.

Unilateral application of 50 µL of 0.5%, 1%, or 2% flunarizine reduced IOP bilaterally. In the treated glaucomatous eyes, flunarizine reduced the IOP for 2, 3, or 5 hours, with a maximum reduction of 2.5 ± 0.5 (mean ± SEM) mm Hg (9%), 3.0 ± 0.4 mm Hg (10%), and 5.0 ± 0.8 mm Hg (18%) following the 0.5%, 1%, and 2% concentrations, respectively (P < 0.01). The maximum reductions in IOP in the contralateral untreated eyes were 1.3 ± 0.5 mm Hg, 1.5 ± 0.3 mm Hg, and 2.9 ± 0.7 mm Hg following the 0.5%, 1%, and 2% concentrations, respectively (P < 0.05). Both the magnitude and duration of the ocular hypotensive effect of 0.5% flunarizine were enhanced with twice-daily administration for 5 days. Outflow facility in normal monkeys was impacted, as indicated by measurements taken in the study.

---

### Medication reviews and deprescribing as a single intervention in falls prevention: a systematic review and meta-analysis [^115j95xx]. Age and Ageing (2022). Low credibility.

Falls incidents are a common and growing threat to both the immediate and long-term health and functional independence of older adults. Approximately a third of community dwellers aged 65 years and older will sustain at least one fall each year. In long-term care settings, fall injuries are even more prevalent, with over half of the residents experiencing falls annually. Furthermore, falls are the most frequently reported safety incident among adult inpatients.

Falls are generally multifactorial, often resulting from several interacting risks. The burden related to fall injuries, both from individual and societal perspectives, underscores the importance of identifying effective falls prevention approaches, such as appropriate multifactorial interventions.

A crucial component of a multifactorial falls prevention strategy is medication review. This process involves the judicious deprescribing of certain medications. The rationale behind this intervention is that the potential adverse effects of fall-risk-increasing drugs (FRIDs) — such as orthostatic hypotension and sedation — are reversible after deprescribing. However, there is uncertainty regarding the effectiveness of medication review and deprescribing interventions when used as a single intervention for falls prevention.

At the time of writing, few systematic reviews and meta-analyses have focused on this topic. Comparing these systematic reviews has proven challenging due to the variation of included trials. The most recent systematic review found no effect of FRIDs deprescribing on fall prevention.

---

### Edluar [^116p8fBr]. U.S. Food and Drug Administration (2022). High credibility.

Inform patients and their families about the benefits and risks of treatment with Edluar. Inform patients of the availability of a Medication Guide and instruct them to read the Medication Guide prior to initiating treatment with Edluar and with each prescription refill. Review the Edluar Medication Guide with every patient before initiation of treatment. Instruct patients or caregivers that Edluar should be taken only as prescribed.

- **Complex sleep behaviors**: Instruct patients and their families that Edluar may cause complex sleep behaviors, including sleep-walking, sleep-driving, preparing and eating food, making phone calls, or having sex while not being fully awake. Serious injuries and death have occurred during complex sleep behavior episodes. Tell patients to discontinue Edluar and notify their healthcare provider immediately if they develop any of these symptoms [see Boxed Warning, Warnings and Precautions (5.1)].

- **CNS-depressant effects and next-day impairment**: Inform patients that Edluar has the potential to cause next-day impairment, and that this risk is increased if dosing instructions are not carefully followed. Advise patients to wait for at least 8 hours after dosing before driving or engaging in other activities requiring full mental alertness. Let patients know that impairment can be present despite feeling fully awake. Warn patients that increased drowsiness and decreased consciousness may increase the risk of falls in some patients [see Warnings and Precautions (5.2)].

---

### Beta-blockers for hypertension [^114NbSxd]. The Cochrane Database of Systematic Reviews (2017). Low credibility.

Proper understanding of the evidence for beta-blocker therapy in hypertension requires a regularly updated systematic, comprehensive, and appropriate analysis of all currently available data. In 2007, we published a Cochrane Review which re-assessed the place of beta-blockers as first-line therapy for hypertension relative to each of the other major classes of antihypertensive drugs. An update of the review was published in 2012. The review is an update of the 2012 review.

---

### Antihistamines for the common cold [^111maPqm]. The Cochrane Database of Systematic Reviews (2015). High credibility.

The common cold is an upper respiratory tract infection, most commonly caused by a rhinovirus. It affects people of all age groups, and although it is self-limiting in most cases, the common cold still causes significant morbidity. Antihistamines are commonly offered over the counter to relieve symptoms for patients affected by the common cold; however, there is not much evidence of their efficacy.

- **Objectives**: To assess the effects of antihistamines on the common cold.

- **Search methods**: We searched CENTRAL (2015, Issue 6), MEDLINE (1948 to July week 4, 2015), EMBASE (2010 to August 2015), CINAHL (1981 to August 2015), LILACS (1982 to August 2015), and Biosis Previews (1985 to August 2015).

- **Selection criteria**: We selected randomized controlled trials (RCTs) using antihistamines as monotherapy for the common cold. We excluded any studies with combination therapy or using antihistamines in patients with an allergic component in their illness.

- **Data collection and analysis**: Two authors independently assessed trial quality and extracted data. We collected adverse effects information from the included trials.

- **Main results**: We included 18 RCTs, which were reported in 17 publications (one publication reports on two trials) with 4342 participants (of which 212 were children) suffering from the common cold, both naturally occurring and experimentally induced. The interventions consisted of an antihistamine as monotherapy compared with placebo. In adults, there was a short-term beneficial effect of antihistamines on the severity of overall symptoms on day one or two of treatment.

---

### Mental health gap action programme (mhGAP) guideline for mental, neurological and substance use disorders [Internet] [^114quTJt]. Geneva: World Health Organization (2023). High credibility.

For the medical management of bipolar disorder, specifically regarding the management of acute mania, the WHO 2023 guidelines recommend offering oral antipsychotics (aripiprazole, haloperidol, olanzapine, paliperidone, or quetiapine) or mood stabilizers (carbamazepine, lithium, or valproic acid) to adult patients experiencing a manic episode. Careful consideration should be given to balancing effectiveness, potential side effects, and individual patient preferences.

---

### Vestibular migraine treatment: a comprehensive practical review [^113Li6By]. Brain (2022). Low credibility.

- **Calcium channel blockers**: The non-selective diphenylpiperazine calcium channel blockers (flunarizine, lomerizine, cinnarizine) have been used in migraine treatment since the 1980s. This particular class has widespread pharmacodynamic effects: flunarizine and cinnarizine also antagonize H₁ histamine and D₂ dopamine receptors, while lomerizine antagonizes 5-HT₂A receptors. Verapamil was also historically used for migraine prophylaxis, although it is now more commonly used for cluster headache. Four studies looked exclusively at calcium channel blockers, and four multiple-treatment-arm studies included a calcium channel blocker arm.

Lomerizine was examined in one retrospective uncontrolled study, where patients were treated initially with dietary advice alone, and lomerizine 10 mg daily was commenced if the dietary advice was unsuccessful or had been tried previously. Treatment duration and follow-up were variable (personal correspondence with author), and there was no comparator group. Nineteen of the 22 patients treated with lomerizine reported at least 75% reduction in vertigo frequency.

---

### Vestibular migraine treatment: a comprehensive practical review [^115wydGg]. Brain (2022). Low credibility.

- **Preventative treatment**: Details of the 23 studies on prophylactic treatment are contained in Supplementary Table 2.

- **Pharmacological treatment**:

---

### Systemic pharmacological interventions for Ménière's disease [^113EPRmj]. The Cochrane Database of Systematic Reviews (2023). High credibility.

We assessed several types of interventions, including betahistine, diuretics, antihistamines (other than betahistine), antiviral medication, and corticosteroids. Studies using any systemic route of administration, such as oral or parenteral, were included. Intratympanic administration of corticosteroids is addressed in a separate review by Webster (2021a) and is not included here. Betahistine, with its histamine antagonist and agonist effects, was considered separately from other antihistamines.

- **Main comparisons**: Betahistine versus placebo/no treatment, diuretics versus placebo/no treatment, antihistamines versus placebo/no treatment, antivirals versus placebo/no treatment, steroids versus placebo/no treatment.

- **Concurrent treatments**: There were no limitations on the type of concurrent treatments used, as long as they were applied equally in each study arm. Studies that included concurrent treatments were pooled with those where participants did not receive any concurrent treatment. We planned to conduct a subgroup analysis to determine whether effect estimates differed for those receiving additional treatment. However, due to a limited number of studies, this was not possible (refer to the 'Subgroup analysis and investigation of heterogeneity' section).

- **Types of outcome measures**: We assessed all outcomes at intervals of 3 to 12 months. For adverse event data, we used the longest follow-up period available. We also searched the COMET database for existing core outcome sets of relevance.

---

### Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial [^11442xYm]. Cephalalgia (2020). High credibility.

Few migraine preventive agents have been assessed in a pediatric population. We evaluated the safety and efficacy of cinnarizine and sodium valproate for migraine prophylaxis in children and adolescents.

- **Methods**: We carried out a randomized double-blind placebo-controlled trial in the Children's Medical Center and Sina Hospital, Tehran, Iran. Eligible participants were randomly assigned in a 1:1:1 ratio via an interactive web response system to receive either cinnarizine, sodium valproate, or placebo. The primary endpoints were the mean change in frequency and intensity of migraine attacks from baseline to the last 4 weeks of the trial. The secondary endpoint was the efficacy of each drug in the prevention of migraine. The drug was considered effective if it decreased migraine frequency by more than 50% in the double-blind phase compared with the baseline. The safety endpoint was adverse effects reported by children or their parents.

- **Results**: A total of 158 children participated. The frequency of migraine attacks significantly reduced compared to baseline in cinnarizine (difference: -8.0; 95% confidence interval (CI): -9.3 to -6.6), sodium valproate (difference: -8.3; 95% confidence interval: -9.3 to -7.2), and placebo (difference: -4.4; 95% confidence interval: -5.4 to -3.4) arms. The decrease was statistically greater in cinnarizine (difference: -3.6; 95% confidence interval: -5.5 to -1.6) and sodium valproate (difference: -3.9; 95% confidence interval: -5.8 to -1.9) arms, compared to the placebo group. Children in all groups had a significant reduction in intensity of migraine attacks.

---

### Intravenous cetirizine versus intravenous diphenhydramine for the treatment of acute urticaria: A phase III randomized controlled noninferiority trial [^113Mcf9M]. Annals of Emergency Medicine (2020). High credibility.

Acute urticaria is a frequent presentation in emergency departments (EDs), urgent care centers, and other clinical arenas. Treatment options are limited if diphenhydramine is the only intravenous antihistamine offered because of its short duration of action and well-known adverse effects. This study evaluates cetirizine injection, the first second-generation injectable antihistamine, for acute urticaria in a multicenter, randomized, noninferiority, phase 3 clinical trial.

Adult patients presenting to EDs and urgent care centers with acute urticaria requiring an intravenous antihistamine were randomized to either intravenous cetirizine 10 mg or intravenous diphenhydramine 50 mg. The primary endpoint was the 2-hour pruritus score change from baseline, with time spent in the treatment center and rate of return to treatment centers as key secondary endpoints. Frequency of sedation and anticholinergic adverse effects was also recorded.

Among 262 enrolled patients, the 2-hour pruritus score change from baseline for intravenous cetirizine was statistically noninferior to that for intravenous diphenhydramine (-1.6 versus -1.5; 95% confidence interval -0.1 to 0.3) and in favor of cetirizine. Treatment differences also favored cetirizine for mean time spent in the treatment center (1.7 versus 2.1 hours; p = 0.005), return to the treatment center (5.5% versus 14.1%; p = 0.02), lower change from baseline sedation score at 2 hours (0.1 versus 0.5; p = 0.03), and adverse event rate (3.9% versus 13.3%).

Intravenous cetirizine is an effective alternative to intravenous diphenhydramine for treating acute urticaria, demonstrating similar efficacy with a better safety profile in terms of sedation and adverse events.

---

### Symbicort [^112d1eb4]. U.S. Food and Drug Administration (2019). High credibility.

**Diuretics**: The ECG changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of Symbicort with non-potassium-sparing diuretics.

---

### Levocetirizine dihydrochloride [^1146EJS2]. U.S. Food and Drug Administration (2018). Low credibility.

The effectiveness of levocetirizine dihydrochloride 1.25 mg once daily (for ages 6 months to 5 years) and 2.5 mg once daily (for ages 6 to 11 years) in treating symptoms of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria is based on the extrapolation of demonstrated efficacy of levocetirizine dihydrochloride 5 mg once daily in patients aged 12 years and older, supported by pharmacokinetic comparisons between adults and children.

Cross-study comparisons show that administering a 5 mg dose of levocetirizine dihydrochloride to pediatric patients aged 6 to 12 years with seasonal allergic rhinitis results in approximately twice the systemic exposure (AUC) observed when 5 mg is administered to healthy adults. Therefore, children aged 6 to 11 years should not exceed the recommended dose of 2.5 mg once daily. A population pharmacokinetics study indicates that administering 1.25 mg once daily in children aged 6 months to 5 years results in systemic exposure comparable to 5 mg once daily in adults [see Dosage and Administration (2.2); Clinical Studies (14); and Clinical Pharmacology (12.3)].

- **Geriatric use**: Clinical studies of levocetirizine dihydrochloride for approved indications did not include enough patients aged 65 years and older to determine if they respond differently than younger patients. Clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be…

---

### Promethazine: A review of therapeutic uses and toxicity [^11381S3E]. The Journal of Emergency Medicine (2025). Low credibility.

Promethazine was first approved in 1951 and has since been used as a treatment option for a variety of indications. A histamine H₁ receptor competitive antagonist with antihistaminic, sedative, anti-kinetotic, antiemetic, and antimuscarinic effects, promethazine is utilized for the treatment of nausea and vomiting, a common reason for emergency department visits.

- **Objective**: This review of promethazine explores its pharmacology and history of toxicities and discusses recommendations from patient safety organizations, which implicate its role in therapy.

- **Discussion**: Injectable promethazine utilization should take into consideration patient-specific factors, institutional policies, medication shortages of alternative agents, and the efficacy and toxicities of injectable promethazine itself. For decades, injectable promethazine has been associated with rare but serious limb-threatening adverse effects after extravasation or inadvertent intra-arterial injection. Patient safety organizations have called for hospitals to remove injectable promethazine from formularies, and the U.S. Food and Drug Administration acted in December of 2023 to change the product labeling, adding dilution and administration recommendations for intravenous administration and stating a preference for intramuscular administration.

- **Conclusion**: Promethazine offers a suitable alternative antiemetic for use in the emergency department due to its distinct mechanism of action. Injectable promethazine, however, must be used with caution to minimize the risk of serious patient harm in the event of intra-arterial injection.

---

### The European insomnia guideline: An update on the diagnosis and treatment of insomnia 2023 [^1154fbCW]. Journal of Sleep Research (2023). High credibility.

Regarding medical management for insomnia, specifically concerning antihistamines, the EIN/ESRS 2023 guidelines recommend not using antihistamines for the treatment of insomnia.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^115ATy5M]. The Cochrane Database of Systematic Reviews (2023). High credibility.

- **Discussion**

- **Summary of main results**: We identified only three studies for inclusion in this review. They evaluated two of our proposed interventions of interest: beta-blockers and calcium channel blockers for prophylaxis of vestibular migraine.

- **Beta-blockers versus placebo**: One study assessed this comparison. Participants were randomized to receive either 95 mg of metoprolol once daily or a placebo. Metoprolol may make little or no difference to the frequency of vertigo episodes, disease-specific quality of life, and the frequency of headaches at between three and six months of follow-up. The evidence regarding the occurrence of serious adverse effects was very uncertain. The other outcomes we prioritized in this review were not reported by the authors of this study (improvement in vertigo, improvement in other migrainous symptoms, and other adverse effects).

- **Calcium channel blockers versus no intervention**: Two studies evaluated this comparison, both using a dose of 10 mg flunarizine daily. All of the evidence for this comparison was of very low certainty. Participants receiving flunarizine may be more likely to report improvement in vertigo (when assessed using a global score of vertigo symptoms), but the evidence is very uncertain. The frequency of vertigo episodes may also be slightly reduced for those who receive flunarizine but, again, the certainty of the evidence was very low. The evidence was very uncertain about the effect of flunarizine on improvement in vertigo (when assessed as a dichotomous outcome, rather than using a continuous scale) and headache.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^1176wwGe]. The Cochrane Database of Systematic Reviews (2023). High credibility.

The studies evaluated two of our comparisons of interest. One study evaluated metoprolol succinate [Bayer 2019], and the other two studies evaluated flunarizine [Lepcha 2014; Yuan 2016].

- **Beta-blockers versus placebo**: This comparison was evaluated by Bayer 2019. The authors used a dose of 95 mg oral metoprolol succinate once daily for a period of six months. Short periods of up-titration (one week of 47.5 mg daily) and tapering (two weeks of 47.5 mg daily) were also included at the start and end of the study.

- **Calcium channel blockers versus no intervention**: Both studies used a dose of 10 mg oral flunarizine once daily, to be taken at night. This was compared to no intervention in the control group.

- **Improvement in vertigo**: For this outcome, we included dichotomous data assessed as the proportion of participants whose vertigo had 'improved' or 'not improved'.
	- **Global score**: The authors of Lepcha 2014 asked participants to rate the improvement in their vertigo symptoms during the study. This was conducted using a five-point scale (0 to 4, with higher scores representing greater improvement) and analyzed by comparing those who had little improvement (score 0 to 2) and those who had marked improvement (score 3 or 4). We considered it likely that this rating would encompass different aspects of vertigo (including the frequency, intensity, and duration of attacks), but this is not explicitly stated in the article. However, interpreting the results from the use of this scale is very challenging.

---

### Medication reviews and deprescribing as a single intervention in falls prevention: A systematic review and meta-analysis [^111skCRy]. Age and Ageing (2022). Low credibility.

We conducted a comprehensive systematic review and meta-analysis assessing the effectiveness of medication review and deprescribing interventions as a single falls prevention intervention by focusing on all care settings in which older people receive healthcare. In total, 49 studies for the qualitative synthesis were identified, with very heterogeneous results. These included interventions such as medication review by a healthcare professional, targeted FRIDs withdrawal by a research team, educational interventions, and the implementation of CDSS.

The heterogeneity precludes us from estimating the effect of medication review and/or deprescribing as a single intervention. However, we assessed the effect of medication reviews on different fall outcomes by pooling the studies with a sufficiently comparable intervention — 17 studies in four different quantitative analyses. No significant effects on fall outcomes of a medication review as a single intervention were found for any of the settings. Thus, although multifactorial falls preventive interventions, including a medication review, have been proven effective, this cannot be concluded for a medication review as a single intervention in falls prevention.

However, there was a trend for a lower number of fallers in the meta-analysis assessing medication reviews in long-term care, possibly indicating that in a frail subgroup of older persons, medication review intervention might be effective also as a single intervention.

---

### Verapamil hydrochloride [^111dgmyA]. U.S. Food and Drug Administration (2023). High credibility.

Verapamil hydrochloride is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle, as well as in conductile and contractile myocardial cells.

- **Mechanism of action**: The precise mechanism of action of verapamil hydrochloride as an antianginal agent remains to be fully determined, but includes the following two mechanisms:

	- **Relaxation and prevention of coronary artery spasm**: Verapamil hydrochloride dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with coronary artery spasm and is responsible for the effectiveness of verapamil hydrochloride in vasospastic (Prinzmetal's or variant) as well as unstable angina at rest. Whether this effect plays any role in classical effort angina is not clear, but studies of exercise tolerance have not shown an increase in the maximum exercise rate-pressure product, a widely accepted measure of oxygen utilization. This suggests that, in general, relief of spasm or dilation of coronary arteries is not an important factor in classical angina.

	- **Reduction of oxygen utilization**: Verapamil hydrochloride regularly reduces the total peripheral resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles.

---

### Clinical practice guideline: Benign paroxysmal positional vertigo (update) [^113tBP8i]. Otolaryngology — Head and Neck Surgery (2017). High credibility.

Regarding the medical management of benign paroxysmal positional vertigo (BPPV), specifically concerning the use of vestibular suppressants, the AAO-HNSF 2017 guidelines recommend not using vestibular suppressant medications, such as antihistamines and/or benzodiazepines, routinely in patients with BPPV.

---

### Scopolamine (hyoscine) for preventing and treating motion sickness [^1154s6r1]. The Cochrane Database of Systematic Reviews (2011). High credibility.

This is an update of a Cochrane Review first published in The Cochrane Library in Issue 3, 2004, and previously updated in 2007 and 2009. Motion sickness, the discomfort experienced when perceived motion disturbs the organs of balance, may include symptoms such as nausea, vomiting, pallor, cold sweats, hypersalivation, hyperventilation, and headaches. The control and prevention of these symptoms involve pharmacological, behavioral, and complementary therapies. Although scopolamine (hyoscine) has been used in the treatment and prevention of motion sickness for decades, there have been no systematic reviews of its effectiveness.

- **Objectives**: To assess the effectiveness of scopolamine versus no therapy, placebo, other drugs, behavioral, and complementary therapy or two or more of the above therapies in combination for motion sickness in persons (both adults and children) without known vestibular, visual, or central nervous system pathology.

- **Search strategy**: We searched the Cochrane Ear, Nose, and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; CINAHL; Web of Science; BIOSIS Previews; Cambridge Scientific Abstracts; ICTRP and additional sources for published and unpublished trials. The date of the most recent search was 14 April 2011.

- **Selection criteria**: All parallel-arm, randomized controlled trials (RCTs) focusing on scopolamine versus no therapy, placebo, other drugs, behavioral and complementary therapy, or two or more of the above therapies in combination were considered. We focused on outcomes relating to these interventions.